Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,144
archived clinical trials in
Ocular

A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated:  9/7/2012
Pfizer Investigational Site
mi
from
Arvada, CO
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated: 9/7/2012
Pfizer Investigational Site
mi
from
Arvada, CO
Click here to add this to my saved trials
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated:  9/7/2012
Pfizer Investigational Site
mi
from
Bridgeport, CT
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated: 9/7/2012
Pfizer Investigational Site
mi
from
Bridgeport, CT
Click here to add this to my saved trials
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated:  9/7/2012
Pfizer Investigational Site
mi
from
Washington,
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated: 9/7/2012
Pfizer Investigational Site
mi
from
Washington,
Click here to add this to my saved trials
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated:  9/7/2012
Pfizer Investigational Site
mi
from
Atlantis, FL
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated: 9/7/2012
Pfizer Investigational Site
mi
from
Atlantis, FL
Click here to add this to my saved trials
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated:  9/7/2012
Pfizer Investigational Site
mi
from
Atlanta, GA
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated: 9/7/2012
Pfizer Investigational Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated:  9/7/2012
Pfizer Investigational Site
mi
from
Bloomingdale, IL
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated: 9/7/2012
Pfizer Investigational Site
mi
from
Bloomingdale, IL
Click here to add this to my saved trials
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated:  9/7/2012
Pfizer Investigational Site
mi
from
Cedar Rapids, IA
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated: 9/7/2012
Pfizer Investigational Site
mi
from
Cedar Rapids, IA
Click here to add this to my saved trials
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated:  9/7/2012
Pfizer Investigational Site
mi
from
Arkansas City, KA
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated: 9/7/2012
Pfizer Investigational Site
mi
from
Arkansas City, KA
Click here to add this to my saved trials
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated:  9/7/2012
Pfizer Investigational Site
mi
from
Bossier City, LA
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated: 9/7/2012
Pfizer Investigational Site
mi
from
Bossier City, LA
Click here to add this to my saved trials
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated:  9/7/2012
Pfizer Investigational Site
mi
from
Baltimore, MD
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated: 9/7/2012
Pfizer Investigational Site
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated:  9/7/2012
Pfizer Investigational Site
mi
from
Boston, MA
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated: 9/7/2012
Pfizer Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated:  9/7/2012
Pfizer Investigational Site
mi
from
Detroit, MI
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated: 9/7/2012
Pfizer Investigational Site
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated:  9/7/2012
Pfizer Investigational Site
mi
from
Duluth, MN
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated: 9/7/2012
Pfizer Investigational Site
mi
from
Duluth, MN
Click here to add this to my saved trials
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated:  9/7/2012
Pfizer Investigational Site
mi
from
Cape Girardeau, MO
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated: 9/7/2012
Pfizer Investigational Site
mi
from
Cape Girardeau, MO
Click here to add this to my saved trials
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated:  9/7/2012
Pfizer Investigational Site
mi
from
Alliance, NE
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated: 9/7/2012
Pfizer Investigational Site
mi
from
Alliance, NE
Click here to add this to my saved trials
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated:  9/7/2012
Pfizer Investigational Site
mi
from
Incline Village, NV
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated: 9/7/2012
Pfizer Investigational Site
mi
from
Incline Village, NV
Click here to add this to my saved trials
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated:  9/7/2012
Pfizer Investigational Site
mi
from
Lebanon, NH
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated: 9/7/2012
Pfizer Investigational Site
mi
from
Lebanon, NH
Click here to add this to my saved trials
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated:  9/7/2012
Pfizer Investigational Site
mi
from
Clifton, NJ
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated: 9/7/2012
Pfizer Investigational Site
mi
from
Clifton, NJ
Click here to add this to my saved trials
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated:  9/7/2012
Pfizer Investigational Site
mi
from
Rochester, NY
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated: 9/7/2012
Pfizer Investigational Site
mi
from
Rochester, NY
Click here to add this to my saved trials
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated:  9/7/2012
Pfizer Investigational Site
mi
from
Asheville, NC
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated: 9/7/2012
Pfizer Investigational Site
mi
from
Asheville, NC
Click here to add this to my saved trials
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated:  9/7/2012
Pfizer Investigational Site
mi
from
Akron, OH
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated: 9/7/2012
Pfizer Investigational Site
mi
from
Akron, OH
Click here to add this to my saved trials
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated:  9/7/2012
Pfizer Investigational Site
mi
from
Ashland, OR
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated: 9/7/2012
Pfizer Investigational Site
mi
from
Ashland, OR
Click here to add this to my saved trials
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated:  9/7/2012
Pfizer Investigational Site
mi
from
Pittsburgh, PA
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated: 9/7/2012
Pfizer Investigational Site
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated:  9/7/2012
Pfizer Investigational Site
mi
from
Anderson, SC
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated: 9/7/2012
Pfizer Investigational Site
mi
from
Anderson, SC
Click here to add this to my saved trials
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated:  9/7/2012
Pfizer Investigational Site
mi
from
Houston, TX
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated: 9/7/2012
Pfizer Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated:  9/7/2012
Pfizer Investigational Site
mi
from
West Jordan, UT
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated: 9/7/2012
Pfizer Investigational Site
mi
from
West Jordan, UT
Click here to add this to my saved trials
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated:  9/7/2012
Pfizer Investigational Site
mi
from
Burke, VA
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated: 9/7/2012
Pfizer Investigational Site
mi
from
Burke, VA
Click here to add this to my saved trials
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated:  9/7/2012
Pfizer Investigational Site
mi
from
Seattle, WA
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Case Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION
Status: Enrolling
Updated: 9/7/2012
Pfizer Investigational Site
mi
from
Seattle, WA
Click here to add this to my saved trials
Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
Status: Enrolling
Updated:  9/11/2012
McDonald Eye Associates
mi
from
Fayetteville, AR
Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
Status: Enrolling
Updated: 9/11/2012
McDonald Eye Associates
mi
from
Fayetteville, AR
Click here to add this to my saved trials
Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
Status: Enrolling
Updated:  9/11/2012
Harvard Eye Associates
mi
from
Laguna Hills, CA
Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
Status: Enrolling
Updated: 9/11/2012
Harvard Eye Associates
mi
from
Laguna Hills, CA
Click here to add this to my saved trials
Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
Status: Enrolling
Updated:  9/11/2012
Center for Excellence in Eye Care
mi
from
Miami, FL
Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
Status: Enrolling
Updated: 9/11/2012
Center for Excellence in Eye Care
mi
from
Miami, FL
Click here to add this to my saved trials
Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
Status: Enrolling
Updated:  9/11/2012
Chicago Cornea Consultants, Ltd.
mi
from
Hoffman Estates, IL
Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
Status: Enrolling
Updated: 9/11/2012
Chicago Cornea Consultants, Ltd.
mi
from
Hoffman Estates, IL
Click here to add this to my saved trials
Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
Status: Enrolling
Updated:  9/11/2012
Jackson Eye
mi
from
Lake Villa, IL
Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
Status: Enrolling
Updated: 9/11/2012
Jackson Eye
mi
from
Lake Villa, IL
Click here to add this to my saved trials
Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
Status: Enrolling
Updated:  9/11/2012
Cincinnati Eye Institute - Northern Kentucky
mi
from
Edgewood, KY
Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
Status: Enrolling
Updated: 9/11/2012
Cincinnati Eye Institute - Northern Kentucky
mi
from
Edgewood, KY
Click here to add this to my saved trials
Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
Status: Enrolling
Updated:  9/11/2012
Charles River Eye Associates
mi
from
Winchester, MA
Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
Status: Enrolling
Updated: 9/11/2012
Charles River Eye Associates
mi
from
Winchester, MA
Click here to add this to my saved trials
Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
Status: Enrolling
Updated:  9/11/2012
Associated Eye Care
mi
from
Stillwater, MN
Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
Status: Enrolling
Updated: 9/11/2012
Associated Eye Care
mi
from
Stillwater, MN
Click here to add this to my saved trials
Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
Status: Enrolling
Updated:  9/11/2012
Ophthalmology Consultants, Ltd.
mi
from
St. Louis, MO
Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
Status: Enrolling
Updated: 9/11/2012
Ophthalmology Consultants, Ltd.
mi
from
St. Louis, MO
Click here to add this to my saved trials
Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
Status: Enrolling
Updated:  9/11/2012
Carolina Eyecare Physicians
mi
from
Mt. Pleasant, SC
Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
Randomized Controlled Trial of Long-term Treatment Effectiveness for Meibomian Gland Dysfunction (MGD) and Dry Eye
Status: Enrolling
Updated: 9/11/2012
Carolina Eyecare Physicians
mi
from
Mt. Pleasant, SC
Click here to add this to my saved trials
Effects of Selective Laser Trabeculoplasty
Effect of Selective Laser Trabeculoplasty (SLT) on Diurnal Intraocular Pressure in Open-Angle Glaucoma Patients on Medical Treatment
Status: Enrolling
Updated:  9/17/2012
University of Kentucky
mi
from
Lexington, KY
Effects of Selective Laser Trabeculoplasty
Effect of Selective Laser Trabeculoplasty (SLT) on Diurnal Intraocular Pressure in Open-Angle Glaucoma Patients on Medical Treatment
Status: Enrolling
Updated: 9/17/2012
University of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
Study Evaluating the Safety and Intraocular Pressure (IOP) Lowering Response of Brimonidine Tartrate Ophthalmic Solution in Subjects With Open Angle Glaucoma or Ocular Hypertension
A Single-Center, Randomized, Double-Masked, Cross-Over Pilot Study Evaluating Safety and IOP Lowering Response of Brimonidine Tartrate Ophthalmic Solution Versus Vehicle in Subjects With Open Angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated:  9/18/2012
Clinical Site
mi
from
Boston, MA
Study Evaluating the Safety and Intraocular Pressure (IOP) Lowering Response of Brimonidine Tartrate Ophthalmic Solution in Subjects With Open Angle Glaucoma or Ocular Hypertension
A Single-Center, Randomized, Double-Masked, Cross-Over Pilot Study Evaluating Safety and IOP Lowering Response of Brimonidine Tartrate Ophthalmic Solution Versus Vehicle in Subjects With Open Angle Glaucoma or Ocular Hypertension
Status: Enrolling
Updated: 9/18/2012
Clinical Site
mi
from
Boston, MA
Click here to add this to my saved trials
Novel Quantification Methods for Fluorescence to Detect Progression in Stargardt Disease
Novel Quantification Methods for Fundus Flavoprotein Fluorescence and Lipofuscin Fluorescence to Detect Progression in Stargardt Disease
Status: Enrolling
Updated:  9/19/2012
Kellogg Eye Center
mi
from
Ann Arbor, MI
Novel Quantification Methods for Fluorescence to Detect Progression in Stargardt Disease
Novel Quantification Methods for Fundus Flavoprotein Fluorescence and Lipofuscin Fluorescence to Detect Progression in Stargardt Disease
Status: Enrolling
Updated: 9/19/2012
Kellogg Eye Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema (the iDEAL Study)
A Randomized, Multi-center, Phase II Study of the Safety, Tolerability, and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema With Involvement of the FoveAL Center (the iDEAL Study)
Status: Enrolling
Updated:  9/24/2012
Wilmer Eye Institute, Johns Hopkins University
mi
from
Baltimore, MD
A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema (the iDEAL Study)
A Randomized, Multi-center, Phase II Study of the Safety, Tolerability, and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema With Involvement of the FoveAL Center (the iDEAL Study)
Status: Enrolling
Updated: 9/24/2012
Wilmer Eye Institute, Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study to Assess the Clinical Efficacy and Safety of VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI]), Also Commercially Known as EYLEA™ in Patients With Branch Retinal Vein Occlusion (BRVO)
Status: Enrolling
Updated:  10/2/2012
Clinical Research Facility
mi
from
Phoenix, AZ
Study to Assess the Clinical Efficacy and Safety of VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI]), Also Commercially Known as EYLEA™ in Patients With Branch Retinal Vein Occlusion (BRVO)
Status: Enrolling
Updated: 10/2/2012
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study to Assess the Clinical Efficacy and Safety of VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI]), Also Commercially Known as EYLEA™ in Patients With Branch Retinal Vein Occlusion (BRVO)
Status: Enrolling
Updated:  10/2/2012
Clinical Research Facility
mi
from
Santa Clara, CA
Study to Assess the Clinical Efficacy and Safety of VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI]), Also Commercially Known as EYLEA™ in Patients With Branch Retinal Vein Occlusion (BRVO)
Status: Enrolling
Updated: 10/2/2012
Clinical Research Facility
mi
from
Santa Clara, CA
Click here to add this to my saved trials
Study to Assess the Clinical Efficacy and Safety of VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI]), Also Commercially Known as EYLEA™ in Patients With Branch Retinal Vein Occlusion (BRVO)
Status: Enrolling
Updated:  10/2/2012
Clinical Research Facility
mi
from
Aurora, CO
Study to Assess the Clinical Efficacy and Safety of VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI]), Also Commercially Known as EYLEA™ in Patients With Branch Retinal Vein Occlusion (BRVO)
Status: Enrolling
Updated: 10/2/2012
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
Study to Assess the Clinical Efficacy and Safety of VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI]), Also Commercially Known as EYLEA™ in Patients With Branch Retinal Vein Occlusion (BRVO)
Status: Enrolling
Updated:  10/2/2012
Clinical Research Facility
mi
from
Bridgeport, CT
Study to Assess the Clinical Efficacy and Safety of VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI]), Also Commercially Known as EYLEA™ in Patients With Branch Retinal Vein Occlusion (BRVO)
Status: Enrolling
Updated: 10/2/2012
Clinical Research Facility
mi
from
Bridgeport, CT
Click here to add this to my saved trials
Study to Assess the Clinical Efficacy and Safety of VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI]), Also Commercially Known as EYLEA™ in Patients With Branch Retinal Vein Occlusion (BRVO)
Status: Enrolling
Updated:  10/2/2012
Clinical Research Facility
mi
from
Daytona Beach, FL
Study to Assess the Clinical Efficacy and Safety of VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI]), Also Commercially Known as EYLEA™ in Patients With Branch Retinal Vein Occlusion (BRVO)
Status: Enrolling
Updated: 10/2/2012
Clinical Research Facility
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
Study to Assess the Clinical Efficacy and Safety of VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI]), Also Commercially Known as EYLEA™ in Patients With Branch Retinal Vein Occlusion (BRVO)
Status: Enrolling
Updated:  10/2/2012
Clinical Research Facility
mi
from
Overland Park, KA
Study to Assess the Clinical Efficacy and Safety of VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI]), Also Commercially Known as EYLEA™ in Patients With Branch Retinal Vein Occlusion (BRVO)
Status: Enrolling
Updated: 10/2/2012
Clinical Research Facility
mi
from
Overland Park, KA
Click here to add this to my saved trials
Study to Assess the Clinical Efficacy and Safety of VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI]), Also Commercially Known as EYLEA™ in Patients With Branch Retinal Vein Occlusion (BRVO)
Status: Enrolling
Updated:  10/2/2012
Clinical Research Facility
mi
from
Baltimore, MD
Study to Assess the Clinical Efficacy and Safety of VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI]), Also Commercially Known as EYLEA™ in Patients With Branch Retinal Vein Occlusion (BRVO)
Status: Enrolling
Updated: 10/2/2012
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study to Assess the Clinical Efficacy and Safety of VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI]), Also Commercially Known as EYLEA™ in Patients With Branch Retinal Vein Occlusion (BRVO)
Status: Enrolling
Updated:  10/2/2012
Clinical Research Facility
mi
from
Boston, MA
Study to Assess the Clinical Efficacy and Safety of VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI]), Also Commercially Known as EYLEA™ in Patients With Branch Retinal Vein Occlusion (BRVO)
Status: Enrolling
Updated: 10/2/2012
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials